Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD5122 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | AZD5122 oral suspension (part A and B) |
| 2 | PLACEBO_COMPARATOR | Placebo oral suspension (part A) |
| 3 | EXPERIMENTAL | AZD5122 oral and IV infusion (part B) |
| Name | Type | Description |
|---|---|---|
| AZD5122 | DRUG | A single dose of oral suspension |
| Placebo | DRUG | A single dose of oral suspension |
Inclusion Criteria: * Provision of signed and dated, written informed consent. * Normal physical examination, laboratory values, blood pressure and pulse * Healthy male caucasian subjects Exclusion Criteria: * Subjects must not have any history of gastrointestinal, hepatic or renal disease, or an...
AZD5122 is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and is in early clinical development. The only completed trial evaluated a single dose in healthy male subjects to investigate its activity and safety.
AZD5122 is being developed by AstraZeneca PLC, which trades on the stock exchange under the ticker AZN. The company sponsored the Phase 1 clinical trial of this investigational small molecule.
AZD5122 is in Phase 1 clinical development. The single Phase 1 trial has been completed, and the drug remains investigational. It has not been approved by regulatory authorities, and its safety and efficacy have not been established.
AZD5122 has one completed clinical trial, registered as NCT00984477. This Phase 1 study investigated the activity of a single dose of AZD5122 in healthy male subjects aged 18 years and older in the United Kingdom. The trial enrolled 100 participants and was placebo-controlled and double-blind.
No alternative names for AZD5122 have been disclosed. The drug is identified only by its code name AZD5122 in the clinical trial registry, and no other brand or chemical names have been reported.